NYSE$TEVA

Teva Pharmaceutical Industries ADR · Q1 2025 earnings

Q1 2025 earnings · · Before market open · Investor relations

Briefing

Teva reported Q1 2025 net revenues of $3.8B with net income of $270M and diluted EPS of $0.24.

Net revenues were $3.8 billion as key brands and generics performed in line with plan. Net income was $270 million, or $0.24 per diluted share, with debt reduction and pipeline milestones cited in the quarterly filing.

  • Q1 net revenues $3.8B.
  • Net income $270M; diluted EPS $0.24.
  • Branded and generic portfolio mix.
  • Leverage reduction and pipeline execution.

Headline financials

Total Revenue

$3.89B

Previous: $3.82B+1.9%
EPS (adj)

$0.24

Previous: $0.48-50.0%
Free Cash Flow

$107M

No prior period
Innovative Portfolio Revenue

$589M

No prior period
Capital Expenditures

-$127M

Previous: -$124M-2.4%
Net Income

$220M

Previous: -$139M+258.3%
Operating Income

$0.00

Previous: -$218M+100.0%

Revenue & EPS history

Teva · Revenue · Quarterly

$3.89B

Q1 2025+1.9%vs Q1 2024
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Teva · $1.85B total across 3 segments · Q3 2023

  • Europe
    $1.15B+7.2%
  • International Markets
    $485M+2.1%
  • Other Activities
    $217M

Forward guidance

Management discusses operating priorities, capital allocation, and sector risks in the quarterly filing.

Tailwinds

  • Headline results and segment trends anchor the quarter.
  • Liquidity and balance-sheet capacity support operations.
  • Strategic initiatives outlined in MD&A.

Headwinds

  • Macro, rates, or input costs may pressure margins.
  • One-time items affect year-over-year comparability.
  • Execution risk on growth or restructuring plans.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

+0.3%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+0.7%

Avg return

30 days after

51%

38 / 74 earnings

Positive

+27.1%

Q2 2022

Best reaction

-34.1%

Q2 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.1%+11.9%+11.7%
Q4 2025+2.1%+9.2%+4.1%
Q3 2025+20.4%+18.6%+39.1%
Q2 2025+1.8%-5.1%+11.1%
Q1 2025+8.9%+11.4%+10.2%
Q4 2024-13.9%-19.4%-23.5%
Q3 2024-6.8%-7.5%-7.7%
Q2 2024+6.9%+1.6%+15.0%
Q1 2024+14.7%+21.0%+20.6%
Q4 2023+6.2%+5.5%+15.1%
Q3 2023-3.0%-2.4%+8.6%
Q2 2023+15.4%+16.2%+18.7%
Q1 2023-9.8%-11.3%-19.5%
Q4 2022-9.8%-5.4%-16.3%
Q3 2022-3.3%+3.7%-1.1%
Q2 2022+27.1%+30.5%+37.6%
Q1 2022-2.3%-8.1%+11.6%
Q4 2021+6.3%+2.8%-9.8%
Q3 2021-7.0%-1.7%-9.6%
Q2 2021+8.6%+10.4%+4.8%
Q1 2021+2.6%+4.2%+0.3%
Q4 2020-11.8%-13.2%-15.8%
Q3 2020-1.0%+4.5%+11.6%
Q2 2020+3.0%+0.6%-22.1%
Q1 2020+7.7%+9.0%+22.5%
Q4 2019+1.9%-0.9%-31.9%
Q3 2019+14.8%+18.6%+22.5%
Q2 2019+3.3%-0.6%-0.7%
Q1 2019-0.3%-4.1%-43.2%
Q4 2018-9.6%-6.0%-13.7%
Q3 2018+13.1%+15.6%+7.8%
Q2 2018-7.1%-2.5%-4.0%
Q1 2018-4.1%+1.6%+17.7%
Q4 2017-10.7%-11.2%-8.0%
Q3 2017-18.7%-16.6%+8.8%
Q2 2017-34.1%-16.2%-39.4%
Q1 2017+1.7%+1.3%-3.6%
Q4 2016+8.4%+9.4%+6.7%
Q3 2016-7.2%-6.0%-10.5%
Q2 2016+1.2%-6.2%-8.8%
Q1 2016+5.2%+1.7%+10.8%
Q4 2015-2.0%
Q3 2015-5.1%
Q2 2015-2.6%
Q1 2015+0.1%
Q3 2014+3.6%
Q4 2014+2.0%
Q2 2014-1.6%
Q1 2014+2.0%
Q4 2013-1.9%
Q3 2013-1.5%
Q2 2013-2.0%
Q1 2013+1.0%
Q4 2012+1.4%
Q3 2012+2.6%
Q2 2012-3.3%
Q1 2012-5.4%
Q4 2011+2.5%
Q3 2011+7.0%
Q2 2011+1.9%
Q1 2011+5.6%
Q4 2010+0.4%
Q3 2010+0.3%
Q2 2010-3.4%
Q1 2010+0.9%
Q4 2007+1.2%
Q4 2009+1.2%
Q3 2008-1.4%
Q3 2009-1.4%
Q2 2008-0.8%
Q2 2009-0.8%
Q1 2009-0.6%
Q1 2008-0.6%
Q4 2008-0.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro